Abveris Presents Integrated Antibody Discovery Workflows Targeting the SARS-CoV-2 Spike Protein for COVID-19 Research
Canton, MA, USA – Abveris, Inc. today announced the...
- Therapeutic antibodies against difficult targets such as GPCR, ion channels, glycan targets
- Cell therapies
- Point-of-care diagnostics
- Reagent & anti-idiotypic antibodies supporting clinical trials
- Anywhere else antibodies are needed
Pharma and biotech of various sizes and pipelines rely on Abveris.
Speak with Abveris scientists about how to tackle challenges in antibody discovery.